Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Clazakizumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : CSL
Deal Size : Undisclosed
Deal Type : Acquisition
CSL Behring to Acquire Biotech Company Vitaeris
Details : With this acquisition, clazakizumab joins CSL842 and CSL964 as part of CSL Behring’s portfolio of products in late-stage development to address significant unmet needs in the transplant community.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 08, 2020
Lead Product(s) : Clazakizumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : CSL
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?